SSM

Oncology·MeSH: Immune Complex Diseases

13 drugs in development·9 companies·1 clinical trial

Drug Pipeline by Phase

Approved(8)

Drug	Company
aPROMISE (commercialized as PYLARIFY AI in the U.S.)	Lantheus Holdings, Inc. (LNTH)
edluar	Viatris Inc (VTRS)
medroxyprogesterone	Amphastar Pharmaceuticals, Inc. (AMPH)
nodify cdt	Biodesix Inc. (BDSX)
nodify xl2	Biodesix Inc. (BDSX)
ovawatch	Aspira Women's Health Inc. (AWHL)
xl2	Biodesix Inc. (BDSX)
zolpidem	Teva Pharmaceutical Industries Limited (TEVA)

Phase 3(1)

Drug	Company
bezuclastinib (CGT9486)	Cogent Biosciences, Inc. (COGT)

Phase 2(1)

Drug	Company
Bezuclastinib	Cogent Biosciences, Inc. (COGT)

Unknown(3)

Drug	Company
HeartRisk™	Cardio Diagnostics Holdings Inc. (CDIO)
lunre+camo	Repare Therapeutics Inc. (RPTX)
PrecisionCHD™	Cardio Diagnostics Holdings Inc. (CDIO)

BioSniper tracks 13 drugs in development for SSM across 9 companies.

There are 1 clinical trial targeting SSM tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.